Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance

Go back to Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance

WallachBeth Capital Upgrades DepoMed Inc (DEPO) to Buy

November 11, 2015 7:34 AM EST

WallachBeth Capital upgraded DepoMed Inc (NASDAQ: DEPO) from Hold to Buy with a price target of $33.00.

For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.

Shares of DepoMed Inc closed at $21.21 yesterday.

... More

Depomed (DEPO) Reports 3Q EPS Beat; Janney Capital Reiterates Buy

November 10, 2015 9:25 AM EST

Janney Capital reiterated a Buy rating and $35.00 price target on DepoMed Inc (NASDAQ: DEPO) following the company's 3Q earnings report. DEPO reports $104.9 mln in revenues and non-GAAP adjusted EPS of $0.33, easily beating consensus estimates of $$101.64 mln and non-GAAP adjusted earnings of $0.19 per share.

Analyst... More

Depomed (DEPO) Tops Q3 EPS by 14c

November 9, 2015 4:04 PM EST

Depomed (NASDAQ: DEPO) reported Q3 EPS of $0.33, $0.14 better than the analyst estimate of $0.19. Revenue for the quarter came in at $105 million versus the consensus estimate of $101.64 million.

Opportunities for Sustained Growth·

NUCYNTA is strongly positioned... More